Literature DB >> 17621621

The SAFE (SGRQ score, air-flow limitation and exercise tolerance) Index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease.

Mohd Shah Azarisman1, Mohd Anshar Fauzi, Mohd Perdaus Ahmad Faizal, Zaharim Azami, Abdul Manap Roslina, Harun Roslan.   

Abstract

BACKGROUND: This study was proposed to develop a composite of outcome measures using forced expiratory volume percentage of predicted, exercise capacity and quality of life scores for assessment of chronic obstructive pulmonary disease (COPD) severity.
MATERIALS AND METHODS: Eighty-six patients with COPD were enrolled into a prospective, observational study at the respiratory outpatient clinic, National University Hospital Malaysia (Hospital Universiti Kebangsaan Malaysia--HUKM), Kuala Lumpur.
RESULTS: Our study found modest correlation between the forced expiratory volume in 1 s (FEV(1)), 6 min walk distance and the SGRQ scores with mean (SD) values of 0.97 (0.56) litres/s, 322 (87) m and 43.7 (23.6)%, respectively. K-Means cluster analysis identified four distinct clusters which reached statistical significance which was refined to develop a new cumulative staging system. The SAFE Index score correlated with the number of exacerbations in 2 years (r = 0.497, p<0.001).
CONCLUSION: We have developed the SGRQ, Air-Flow limitation and Exercise tolerance Index (SAFE Index) for the stratification of severity in COPD. This index incorporates the SGRQ score, the FEV(1) % predicted and the 6 min walk distance. The SAFE Index is moderately correlated with the number of disease exacerbations.

Entities:  

Mesh:

Year:  2007        PMID: 17621621      PMCID: PMC2600092          DOI: 10.1136/pgmj.2006.052399

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  23 in total

1.  Is lung function really a good parameter in evaluating the long-term effects of inhaled corticosteroids in COPD?

Authors:  C P van Schayck
Journal:  Eur Respir J       Date:  2000-02       Impact factor: 16.671

Review 2.  The importance of spirometry in COPD and asthma: effect on approach to management.

Authors:  B R Celli
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

3.  Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease.

Authors:  I M Osman; D J Godden; J A Friend; J S Legge; J G Douglas
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

4.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; E A Paul; J C Bestall; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  1998-05       Impact factor: 21.405

5.  Quality of life and exercise tolerance in chronic obstructive pulmonary disease: effects of a short and intensive inpatient rehabilitation program.

Authors:  D Fuchs-Climent; D Le Gallais; A Varray; J Desplan; M Cadopi; C Préfaut
Journal:  Am J Phys Med Rehabil       Date:  1999 Jul-Aug       Impact factor: 2.159

Review 6.  Chronic obstructive pulmonary disease outcome measurements: what's important? What's useful?

Authors:  Nicholas J Gross
Journal:  Proc Am Thorac Soc       Date:  2005

7.  Relationship of upper-limb and thoracic muscle strength to 6-min walk distance in COPD patients.

Authors:  Victor Zuniga Dourado; Letícia Cláudia de Oliveira Antunes; Suzana Erico Tanni; Sergio Alberto Rupp de Paiva; Carlos Roberto Padovani; Irma Godoy
Journal:  Chest       Date:  2006-03       Impact factor: 9.410

8.  Measurement of health-related quality of life in the national emphysema treatment trial.

Authors:  Robert M Kaplan; Andrew L Ries; John Reilly; Zab Mohsenifar
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

9.  Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD.

Authors:  R E Wegner; R A Jörres; D K Kirsten; H Magnussen
Journal:  Eur Respir J       Date:  1994-04       Impact factor: 16.671

10.  Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD.

Authors:  Elisabeth Ståhl; Sven-Arne Jansson; Ann-Christin Jonsson; Klas Svensson; Bo Lundbäck; Fredrik Andersson
Journal:  Health Qual Life Outcomes       Date:  2003-06-02       Impact factor: 3.186

View more
  13 in total

1.  Machine Learning and Prediction of All-Cause Mortality in COPD.

Authors:  Matthew Moll; Dandi Qiao; Elizabeth A Regan; Gary M Hunninghake; Barry J Make; Ruth Tal-Singer; Michael J McGeachie; Peter J Castaldi; Raul San Jose Estepar; George R Washko; James M Wells; David LaFon; Matthew Strand; Russell P Bowler; MeiLan K Han; Jorgen Vestbo; Bartolome Celli; Peter Calverley; James Crapo; Edwin K Silverman; Brian D Hobbs; Michael H Cho
Journal:  Chest       Date:  2020-04-27       Impact factor: 9.410

2.  Chronic obstructive pulmonary disease phenotypes: the future of COPD.

Authors:  MeiLan K Han; Alvar Agusti; Peter M Calverley; Bartolome R Celli; Gerard Criner; Jeffrey L Curtis; Leonardo M Fabbri; Jonathan G Goldin; Paul W Jones; William Macnee; Barry J Make; Klaus F Rabe; Stephen I Rennard; Frank C Sciurba; Edwin K Silverman; Jørgen Vestbo; George R Washko; Emiel F M Wouters; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

Review 3.  Heterogeneity of chronic obstructive pulmonary disease: from phenotype to genotype.

Authors:  Xu Chen; Xiaomao Xu; Fei Xiao
Journal:  Front Med       Date:  2013-12       Impact factor: 4.592

Review 4.  Multidimensional prognostic indices for use in COPD patient care. A systematic review.

Authors:  Wouter D van Dijk; Lisette van den Bemt; Saskia van den Haak-Rongen; Erik Bischoff; Chris van Weel; Johannes C C M in 't Veen; Tjard R J Schermer
Journal:  Respir Res       Date:  2011-11-14

5.  Multiple Score Comparison: a network meta-analysis approach to comparison and external validation of prognostic scores.

Authors:  Sarah R Haile; Beniamino Guerra; Joan B Soriano; Milo A Puhan
Journal:  BMC Med Res Methodol       Date:  2017-12-21       Impact factor: 4.615

6.  A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.

Authors:  Matthew Strand; Erin Austin; Matthew Moll; Katherine A Pratte; Elizabeth A Regan; Lystra P Hayden; Surya P Bhatt; Aladin M Boriek; Richard Casaburi; Edwin K Silverman; Spyridon Fortis; Ingo Ruczinski; Harald Koegler; Harry B Rossiter; Mariaelena Occhipinti; Nicola A Hanania; Hirut T Gebrekristos; David A Lynch; Ken M Kunisaki; Kendra A Young; Jessica C Sieren; Margaret Ragland; John E Hokanson; Sharon M Lutz; Barry J Make; Gregory L Kinney; Michael H Cho; Massimo Pistolesi; Dawn L DeMeo; Frank C Sciurba; Alejandro P Comellas; Alejandro A Diaz; Igor Barjaktarevic; Russell P Bowler; Richard E Kanner; Stephen P Peters; Victor E Ortega; Mark T Dransfield; James D Crapo
Journal:  Chronic Obstr Pulm Dis       Date:  2020-10

7.  Indices and COPD.

Authors:  Peter Howard
Journal:  Multidiscip Respir Med       Date:  2010-06-30

8.  Fatigue and multidimensional disease severity in chronic obstructive pulmonary disease.

Authors:  Deniz Inal-Ince; Sema Savci; Melda Saglam; Ebru Calik; Hulya Arikan; Meral Bosnak-Guclu; Naciye Vardar-Yagli; Lutfi Coplu
Journal:  Multidiscip Respir Med       Date:  2010-06-30

9.  Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.

Authors:  Pere Almagro; Pablo Martinez-Camblor; Joan B Soriano; Jose M Marin; Inmaculada Alfageme; Ciro Casanova; Cristobal Esteban; Juan J Soler-Cataluña; Juan P de-Torres; Bartolome R Celli; Marc Miravitlles
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

10.  Prediction of COPD-specific health-related quality of life in primary care COPD patients: a prospective cohort study.

Authors:  Lara Siebeling; Jammbe Z Musoro; Ronald B Geskus; Marco Zoller; Patrick Muggensturm; Anja Frei; Milo A Puhan; Gerben ter Riet
Journal:  NPJ Prim Care Respir Med       Date:  2014-08-28       Impact factor: 2.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.